Navigation Links
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Date:5/7/2009

ed 14.04.09

6. Novartis Data on File (GLI-001-01)

7. Life Raft Group. Managing Initial Recurrence. http://www.liferaftgroup.org/gist_recurrence.html, last accessed 14.04.09

8. Cancerbackup, Gastrointestinal stromal tumours(GIST); http://www.cancerbackup.org.uk/Cancertype/Softtissuesarcomas/Types/GIST, last accessed 14.04.09

9. Choi et al, Response evaluation of Gastrointestinal Stromal Tumors. The Oncologist 2008;13(suppl 2):4-7

10. Cancer Research UK, Cancer help, What is the treatment for GIST - gastrointestinal stromal tumour? ; http://www.cancerhelp.org.uk/help/default.asp?page=6161, last accessed 14.04.09

11. Rubin BP, Heinrich MC, Corless CL; Gastrointestinal stromal tumour. Lancet. 2007 May 19;369(9574):1731-41

12. Corless, CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol 22:3813-3825.

13. Summary of Product Characteristics. Glivec. Last updated 01/02/2008

14. Joensuu H, Fletcher C, Dimitrijevic S et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-64

(Due to the length of some of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

Notes to Editors

About Glivec(R) (Glivec)

Glivec is approved in more than 90 countries including the US, EU and Japan for the treatment of all phases of Ph+ CML. Glivec is also approved in the EU, US and other countries for the treatment of patients with KIT (CD117)-positive gastrointestinal tumours (GIST), which cannot be surgical
'/>"/>

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
2. Bionovo Announces First Quarter 2009 Highlights and Financial Results
3. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
4. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
5. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
6. Transcept Pharmaceuticals to Report First Quarter 2009 Results
7. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
10. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
11. Oakwood Surgeons Perform Worlds First 3D Surgery Without Special Glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
(Date:8/21/2014)... Albany, New York (PRWEB) August 21, 2014 ... Transparency Market Research "Medical Fiber Optics Market-Global Industry Analysis, ... the global medical fiber optics market was valued at ... grow at a CAGR of 7.6% from 2013 to ... million in 2019. , The medical fiber optics market ...
(Date:8/21/2014)... According to a new market report published by ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - ... USD 236.1 million in 2011 and is estimated to ... at a CAGR of 6.3% from 2012 to 2018. ... http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth in recent ...
(Date:8/21/2014)... 21, 2014 The worlds of personal ... an exciting chance to grab free products. BaliniSports ... from Tom's of Maine with all qualifying purchases for ... our environmentally friendly yoga apparel is simply perfect,” said ... promotion between the two brands is intended to give ...
(Date:8/21/2014)... August 21, 2014 Tibet has long ... the mysterious mountaintop kingdom. Prayers flags whip in ... and the low rumble of chanting monks fill the ... of the world’, access to Tibet is challenging due ... foreign land can prove to be daunting for even ...
(Date:8/21/2014)... David Mullings’ new book, Things #Entrepreneurs ... collection of quotes from famous entrepreneurs to the not ... entrepreneurs on their challenging paths towards success. Earth Source ... of President and Founder Audrey Darrow alongside the bits ... celebrities such as Oprah Winfrey, Steve Jobs, and Richard ...
Breaking Medicine News(10 mins):Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
... BLU-MED Response Systems,announced today two new contract ... preparedness and surge capacity for hospitals and,public health ... District,Four and Suffolk County, NY., The first ... awarded by the Idaho Central District Health Department. ...
... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
... Calif., Nov. 30 Omnicell, Inc.,(Nasdaq: OMCL ... acute healthcare,facilities, today announced that it has entered ... in an all cash transaction valued at,approximately $26 ... mobile cart technology that brings quality healthcare to ...
... a significantly slower rate of decline in lung function in ... study. , Researchers found that patients with cystic fibrosis ... percent reduction in loss of lung function compared to those ... a period of two to seven years. , It ...
... Specifically for Resource-Limited ... Global Procurement Consortium, UPPSALA, Sweden, November 30 ... an agreement with the Clinton,Foundation HIV/AIDS Initiative (CHAI). Under ... to members of CHAI,s,Procurement Consortium at a discounted price. ...
... AstraZeneca (NYSE:,AZN) today announced that the United States ... six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) for its ... exclusivity being,granted by the FDA, the patent was due ... approved in the US for the for the following,indications:, ...
Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: